Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01609478
First received: April 23, 2012
Last updated: August 27, 2014
Last verified: August 2014
  Purpose

To provide the efficacy, safety and pharmacokinetics of indacaterol acetate in patients with persistent asthma to support dose selection of indacaterol in fixed dose combination QMF149.


Condition Intervention Phase
Asthma
Drug: indacaterol
Drug: placebo
Drug: mometasone furoate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, 12-week Treatment, Parallel-group Study to Assess the Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate (75 and 150 µg o.d.) in Patients With Persistent Asthma

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Trough Forced Expiratory Volume in One Second (FEV1) After 12 Weeks (Day 85) [ Time Frame: after 12 weeks (Day 85) ] [ Designated as safety issue: No ]
    Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 12 weeks (Day 85)


Secondary Outcome Measures:
  • Asthma Control Questionnaire 5 (ACQ-5) After 12 Weeks (Day 85) [ Time Frame: aftert 12 weeks (Day 85) ] [ Designated as safety issue: No ]
    The Asthma Control Questionnaire (ACQ-5) is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). A negative change in score indicates improvement in symptoms. MIXED model: Change from baseline in ACQ-5 = treatment + gender + baseline ACQ-5 score + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.

  • Trough Forced Expiratory Volume in One Second (FEV1) After 2 Weeks (Day 15), 4 Weeks (Day 29), and 8 Weeks (Day 57) of Treatment. [ Time Frame: Day 15, Day 29 and Day 57 ] [ Designated as safety issue: No ]
    Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 2 weeks (Day 15), 4 weeks (Day 29), and 8 weeks (Day 57) of treatment.

  • Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at All Time Points [ Time Frame: Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 ] [ Designated as safety issue: No ]
    Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards. FVC is measured on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at all time points

  • Forced Expiratory Volume in One Second (FEV1)/ Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 [ Time Frame: Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 ] [ Designated as safety issue: No ]
    Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards.

  • Forced Expiratory Flow (FEF 25-75% )on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 [ Time Frame: Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 ] [ Designated as safety issue: No ]
    Forced Expiratory Flow (FEF 25-75%) was measured via spirometry conducted according to internationally accepted standards.

  • Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) at (5 Min - 4 h), (5 Min - 1 h) (1 h - 4 h) Measured on Day 1, 2 Weeks (Day 14)&12 Weeks (Day 84) [ Time Frame: Day 1, 2 Weeks, 12 Weeks ] [ Designated as safety issue: No ]
    Forced Expiratory Volume in 1 second (FEV1)/Area Under the Curve(AUC) was measured via spirometry conducted according to internationally accepted standards.FEV1 AUC(5 min - 4 h), (5 min - 1 h) and (1 h - 4 h) are measured at Day 1, 2 Weeks (Day 14) and 12 Weeks (Day84) and defined as average of FEV1 at specified timepoints above.

  • Peak Forced Expiratory Volume in 1 Second (FEV1) at Day 1, 2 Weeks (Day 14), 12 Weeks (Day 84) [ Time Frame: Day 1, 2 weeks (Day 14), 12 weeks (Day 84) ] [ Designated as safety issue: No ]
    Peak Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Peak FEV1 is defined as the maximum FEV1 during the first 4 h post morning dosing at Day 1, 2Weeks and 12 Weeks.

  • Asthma Control Questionnaire 5 (ACQ-5) After 4 Weeks (Day 29) and After 8 Weeks (Day 57) of Treatment [ Time Frame: after 4 weeks (Day 29) and after 8 weeks (Day 57) ] [ Designated as safety issue: No ]
    The ACQ-5 is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. Each item is graded on a scale of 0-6 and the questions are equally weighted. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).

  • Morning and Evening Peak Expiratory Flow Rate (PEFR) Over 12 Weeks of Treatment. This is LS Mean of the Treatment Period. [ Time Frame: baseline, 4weeks, 8 weeks and 12 weeks ] [ Designated as safety issue: No ]
    PEFR is measured with portable spirometer by participants every morning and evening at home.

  • The Usage of Rescue Medication (Short Acting β2-agonist) Over 12 Weeks of Treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Participants record the number of puffs of rescue medication taken in the previous 12 hours in the morning and nighttime.

  • Asthma Quality of Life Questionnaire (AQLQ(S)) After 4 Weeks (Day 29) and 12 Weeks (Day 85) of Treatment [ Time Frame: 4 Weeks, 12 Weeks ] [ Designated as safety issue: No ]
    The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and > 1.5 as marked clinically important differences for any individual domain or for the overall summary score.

  • Time to First Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Duration of treatment until first asthma exacerbation by severity of exacerbation. A severe asthma exacerbation is systemic corticosteroids (SCS) use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.

  • The Annual Rate of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Annual incidence rate of asthma exacerbation by severity of exacerbation. The number of asthma exacerbation is used to calculate annual incidence rate. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations. Number of the asthma exacerbation will be analyzed by the negative binomial regression including treatment, history of asthma exacerbation in the 12 months prior to screening and region as factors and FEV1 prior to inhalation and FEV1 30 min post inhalation of salbutamol/albuterol (components of SABA reversibility) as covariates. The estimates are obtained from the model and so we cannot specify a formula.

  • Duration of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Duration of asthma exacerbations by severity of exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.

  • The Percentage of Patients With at Least One Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The percentage of patients with at least one asthma exacerbation by severity of exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.

  • Time to Permanent Study Discontinuation Due to Asthma Exacerbation Over the 12 Week Treatment Period [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Time to permanent study discontinuation due to asthma exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.

  • The Percentage of Patients Who Permanently Discontinued Study Due to Asthma Exacerbation Over the 12 Week Treatment Period [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The percentage of patients who permanently discontinued study due to asthma exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.

  • Total Amounts (in Doses) of Systemic Corticosteroids Used to Treat Asthma Exacerbations Over the 12 Week Treatment Period [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Total amounts (in doses) of systemic corticosteroids (SCS) used to treat asthma exacerbations.SCS includes Intramuscular (IM), Intravenous (IV) and Oral. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.

  • Plasma Indacaterol Concentrations at Day 1 and Day 14 [ Time Frame: Day 1 and Day 14 ] [ Designated as safety issue: No ]
    Maximum plasma concentration after drug administration (Cmax) was measured for indacaterol acetate 75 µg and indacaterol acetate 150 µg for Pharmacokinetic (PK) Subgroup


Enrollment: 330
Study Start Date: August 2012
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: indacaterol acetate 75 µg

indacaterol acetate 75 µg od delivered via Concept 1 inhaler

Background therapy: mometasone furoate 200 mcg od

Drug: indacaterol
indacaterol acetate 150 µg indacaterol delivered via Concept 1 inhaler
Drug: mometasone furoate
via Twisthaler inhaler
Experimental: indacaterol acetate 150 µg

indacaterol acetate 150 µg od delivered via Concept 1 inhaler

Background therapy: mometasone furoate 200 mcg od

Drug: indacaterol
indacaterol acetate 150 µg indacaterol delivered via Concept 1 inhaler
Drug: mometasone furoate
via Twisthaler inhaler
Placebo Comparator: placebo

placebo delivered via Concept 1 inhaler

Background therapy: mometasone furoate 200 mcg od

Drug: placebo
placebo delivered via Concept 1 inhaler
Drug: mometasone furoate
via Twisthaler inhaler

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with persistent asthma, diagnosed according to GINA 2010 guideline and who additionally meet the following criteria:
  • Patients who are receiving ICS treatment in a stable regimen for ≥ 4 weeks
  • Patients with a pre-bronchodilator FEV1 value of ≥ 40% and ≤ 80% of predicted normal value
  • Patients who demonstrate an increase of >= 12% and 200 mL in FEV1
  • ACQ-5 score ≥ 1.5

Exclusion Criteria:

  • Patients who are current smokers or have a smoking history of greater than 10 pack years (defined as the number of packs of 20 cigarettes smoked per day multiplied by number of years the patient smoked).
  • Patients with chronic lung disease, including COPD, pulmonary tuberculosis, bronchiectasis, sarcoidosis, interstitial lung disease and cystic fibrosis.
  • Patients with any chronic conditions affecting the respiratory tract (e.g., chronic sinusitis) which in the opinion of the investigator may interfere with the study evaluation or optimal participation in the study.

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01609478

  Hide Study Locations
Locations
Bulgaria
Novartis Investigative Site
Lovech, Bulgaria, 5500
Novartis Investigative Site
Pleven, Bulgaria, 5800
Novartis Investigative Site
Plovdiv, Bulgaria, 4002
Novartis Investigative Site
Ruse, Bulgaria, 7002
Novartis Investigative Site
Sofia, Bulgaria, 1431
Novartis Investigative Site
Sofia, Bulgaria, 1463
Novartis Investigative Site
Sofia, Bulgaria, 1233
Novartis Investigative Site
Sofia, Bulgaria, 1000
Novartis Investigative Site
Sofia, Bulgaria, 1606
Novartis Investigative Site
Sofia, Bulgaria, 1612
Novartis Investigative Site
Sofia, Bulgaria, 1234
Novartis Investigative Site
Varna, Bulgaria, 9020
Novartis Investigative Site
Varna, Bulgaria, 9000
Novartis Investigative Site
Veliko Tarnovo, Bulgaria, 5000
Canada, Ontario
Novartis Investigative Site
Brampton, Ontario, Canada, L6T 0G1
Novartis Investigative Site
Downsview, Ontario, Canada, M3N 2Z9
Novartis Investigative Site
Grimsby, Ontario, Canada, L3M 1P3
Novartis Investigative Site
Hamilton, Ontario, Canada, L8N 3Z5
Novartis Investigative Site
Newmarket, Ontario, Canada, L3Y 5G8
Novartis Investigative Site
Toronto, Ontario, Canada, M9V 4B4
Novartis Investigative Site
Toronto, Ontario, Canada, M5T 3A9
Novartis Investigative Site
Woodstock, Ontario, Canada, N4S 5P5
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H4J 1C5
Novartis Investigative Site
Pointe-Claire, Quebec, Canada, H9R 4S3
Novartis Investigative Site
St-Romuald, Quebec, Canada, G6W 5M6
Novartis Investigative Site
Ste-Foy, Quebec, Canada, G1W 4R4
Germany
Novartis Investigative Site
Bad Woerishofen, Germany, 86825
Novartis Investigative Site
Bonn, Germany, 53123
Novartis Investigative Site
Dortmund, Germany, 44263
Novartis Investigative Site
Dresden, Germany, 01307
Novartis Investigative Site
Frankfurt, Germany, 60596
Novartis Investigative Site
Lübeck, Germany, 23552
Novartis Investigative Site
Mainz, Germany, D-55101
Novartis Investigative Site
Muenchen, Germany, 81677
Novartis Investigative Site
Wiesbaden, Germany, D-65187
Novartis Investigative Site
Wiesloch, Germany, 69168
Japan
Novartis Investigative Site
Yanagawa, Fukuoka, Japan, 832-0059
Novartis Investigative Site
Obihiro, Hokkaido, Japan, 080-0805
Novartis Investigative Site
Sapporo-city, Hokkaido, Japan, 060-0061
Novartis Investigative Site
Ako-shi, Hyogo-Ken, Japan, 678-0241
Novartis Investigative Site
Himeji-city, Hyogo, Japan, 672-8064
Novartis Investigative Site
Naka-gun, Ibaraki, Japan, 319-1113
Novartis Investigative Site
Sakaide, Kagawa, Japan, 762-0031
Novartis Investigative Site
Kyoto-shi, Kyoto-Fu, Japan, 615-8256
Novartis Investigative Site
Tsu, Mie, Japan, 514-1101
Novartis Investigative Site
Oita-shi, Oita-Ken, Japan, 870-0021
Novartis Investigative Site
Beppu, Oita, Japan, 874-0937
Novartis Investigative Site
Kishiwada, Osaka, Japan, 596-8501
Novartis Investigative Site
Machida-shi, Tokyo-To, Japan, 194-0023
Novartis Investigative Site
Ota-ku, Tokyo-To, Japan, 144-0035
Novartis Investigative Site
Chuo-ku, Tokyo, Japan, 103-0027
Novartis Investigative Site
Cyuo-ku, Tokyo, Japan, 104-8560
Novartis Investigative Site
Itabashi, Tokyo, Japan, 173-8610
Novartis Investigative Site
Kiyose-city, Tokyo, Japan, 204-8585
Novartis Investigative Site
Setagaya-ku, Tokyo, Japan, 158-0097
Novartis Investigative Site
Yonezawa, Yamagata, Japan, 992-0045
Novartis Investigative Site
Fukuoka, Japan, 811-1394
Novartis Investigative Site
Gifu, Japan, 502-8558
Korea, Republic of
Novartis Investigative Site
Cheongju, Chungbuk, Korea, Republic of, 361 711
Novartis Investigative Site
Wonju, Gangwon-Do, Korea, Republic of, 220-701
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 110 744
Novartis Investigative Site
Seoul, Korea, Republic of, 120-752
Novartis Investigative Site
Seoul, Korea, Republic of, 100-032
Novartis Investigative Site
Seoul, Korea, Republic of, 158-710
Novartis Investigative Site
Seoul, Korea, Republic of, 152-703
Netherlands
Novartis Investigative Site
Rotterdam, Netherlands, 3045 PM
Novartis Investigative Site
Sittard-Geleen, Netherlands, 6162 BG
Poland
Novartis Investigative Site
Bialystok, Poland, 15-461
Novartis Investigative Site
Bienkowka, Poland, 34-212
Novartis Investigative Site
Bydgoszcz, Poland, 85-046
Novartis Investigative Site
Gdansk, Poland, 80-958
Novartis Investigative Site
Krakow, Poland, 31-023
Novartis Investigative Site
Lodz, Poland, 90-242
Novartis Investigative Site
Lodz, Poland, 90-302
Novartis Investigative Site
Lublin, Poland, 20-637
Novartis Investigative Site
Lublin, Poland, 20-044
Novartis Investigative Site
Torun, Poland, 87-100
Novartis Investigative Site
Wroclaw, Poland, 50-088
Novartis Investigative Site
Znin, Poland, 88-400
Slovakia
Novartis Investigative Site
Banska Bystrica, Slovak Republic, Slovakia, 975 17
Novartis Investigative Site
Bardejov, Slovak Republic, Slovakia, 085 01
Novartis Investigative Site
Levice, Slovak republic, Slovakia, 934 01
Novartis Investigative Site
Dunajska Streda, Slovakia, 929 01
Novartis Investigative Site
Komarno, Slovakia, 945 01
Novartis Investigative Site
Kosice, Slovakia, 040 01
Novartis Investigative Site
Liptovsky Hradok, Slovakia, 033 01
Novartis Investigative Site
Liptovsky Mikulas, Slovakia, 031 23
Novartis Investigative Site
Nove Zamky, Slovakia, 940 01
Novartis Investigative Site
Rimavska Sobota, Slovakia, 979 01
Novartis Investigative Site
Spisská Nová Ves, Slovakia, 052 01
Novartis Investigative Site
Topolcany, Slovakia, 955 01
Novartis Investigative Site
Vysne Hagy, Slovakia, 5984
Novartis Investigative Site
Zvolen, Slovakia, 960 01
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01609478     History of Changes
Other Study ID Numbers: CQMF149E2203, 2012-000520-18
Study First Received: April 23, 2012
Results First Received: June 27, 2014
Last Updated: August 27, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Germany: Federal Institute for Drugs and Medical Devices
Japan: Pharmaceuticals and Medical Devices Agency
Latvia: State Agency of Medicines
Netherlands: Medicines Evaluation Board (MEB)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Slovakia: State Institute for Drug Control
Bulgaria: Bulgarian Drug Agency
Korea: Food and Drug Administration

Keywords provided by Novartis:
asthma

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Mometasone furoate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Allergic Agents

ClinicalTrials.gov processed this record on September 22, 2014